Correspondence 0001213900-24-113353 from InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc.
Date: Dec. 30, 2024 · CIK: 0001728328 · Accession: 0001213900-24-113353
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284029
Letter
INMED PHARMACEUTICALS INC.
Suite 1445 – 885 West Georgia St.
Vancouver, British Columbia, Canada
V6C 3E8
VIA EDGAR
December 30, 2024
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: InMed Pharmaceuticals Inc.
Acceleration Request for Registration Statement on Form S-1
Filed December 23, 2024 (as amended by Pre-Effective
Amendment No. 1 filed on December 30, 2024)
File No. 333-284029
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, InMed Pharmaceuticals Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to December 31, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable.
If you have any questions regarding this request, please contact Jared D. Kaplan of Norton Rose Fulbright US LLP at (312) 964-7754.
Sincerely,
INMED PHARMACEUTICALS INC.
Show Raw Text
CORRESP
1
filename1.htm
INMED PHARMACEUTICALS INC.
Suite 1445 – 885 West Georgia St.
Vancouver, British Columbia, Canada
V6C 3E8
VIA EDGAR
December 30, 2024
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: InMed Pharmaceuticals Inc.
Acceleration Request for Registration Statement on Form
S-1
Filed December 23, 2024 (as amended by Pre-Effective
Amendment
No. 1 filed on December 30, 2024)
File No. 333-284029
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act
of 1933, as amended, InMed Pharmaceuticals Inc. hereby requests that the effective date and time of the above-referenced registration
statement be accelerated to December 31, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable.
If you have any questions regarding this request,
please contact Jared D. Kaplan of Norton Rose Fulbright US LLP at (312) 964-7754.
Sincerely,
INMED PHARMACEUTICALS INC.
/s/ Eric A. Adams
Eric A. Adams
President and Chief Executive Officer
cc:
Netta Jagpal, InMed Pharmaceuticals Inc.
Jared D. Kaplan, Norton Rose Fulbright US LLP
Trevor Zeyl, Norton Rose Fulbright Canada LLP